Cell wall targets in methicillin-resistant staphylococci

Drug Resistance Updates

Volumn 2, Issue 5, 1999, Pages 319-325

  Labischinski, Harald ^a   Johannsen, Lars ^a  

^a Pharma Research Center   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM; BETA LACTAM ANTIBIOTIC; GLYCINE DERIVATIVE; METICILLIN; PEPTIDOGLYCAN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL CELL WALL; BIOSYNTHESIS; DRUG TARGETING; GENE TARGETING; HOSPITAL INFECTION; MEMBRANE BIOLOGY; METABOLISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION;

EID: 0033208340     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.1999.0101     Document Type: Article

References (54)

1. Schentag J. J., Hyatt J. M., Carr J. R. Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections was selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control. Clin Infect Dis. 26:1998;1204-1214.
2. Maranan M. C., Moreira B., Boyle Vavra S. Antimicrobial resistance in staphylococci: Epidemiology, molecular mechanisms, and clinical relevance. Infectious Disease Clinics Of North America. 11:1997;813-849.
3. Noble W. C., Virani Z., Cree R. G. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiology Letters. 72:1992;195-198.
4. Hiramatsu K., Hanaki H., Ino T. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. Journal of Antimicrobial Chemotherapy. 40:1997;135-136.
5. Hiramatsu K., Aritaka N., Hanaki H. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 350:1997;1670-1673.
6. Hiramatsu K. Vancomycin resistance in Staphylococci. Drug Resistance Updates. 1:1998;135-150.
7. Smith T. L., Pearson M. L., Wilcox K. R. Emergence of vancomycin resistance in Staphylococcus aureus. New England Journal of Medicine. 340:1999;493-501.
8. Sieradzki K., Roberts R. B., Haber S. W. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. New England Journal of Medicine. 340:1999;517-523.
9. http://www.tigr.org/tdb/tdb.html.
10. http://www.genome.ou.edu.
11. Holtje J. V. Growth of the stress-bearing and shape-maintaining murein sacculus of Escherichia coli. Microbiology And Molecular Biology Reviews. 62:1998;181-203.
12. Matsuhashi M. Utilization of lipid-linked precursors and the formation of peptidoglycan in the process of cell growth and division: membrane enzymes involved in the final steps of peptidoglycan synthesis and the mechanism of their regulation. Ghuysen J-M., Hakenbeck R., Bacterial Cell Wall. 1994;55-97 Elsevier, New York.
13. van Heijenoort J. Assembly of the monmer unit of bacterial peptidoglycan. Cellular And Molecular Life Sciences. 54:1998;300-304.
14. Giesbrecht P., Kersten T., Maidhof H. Staphylococcal cell wall: Morphogenesis and fatal variations in the presence of penicillin. Microbiology And Molecular Biology Reviews. 62:1998;1371-1414.
15. Goffin C., Ghuysen J. M. Multimodular pencillin binding proteins: An enigmatic family of orthologs and paralogs. Microbiology And Molecular Biology Reviews. 62:1998;1079-1093.
16. Schonbrunn E., Svergun D. I., Amrhein N. Studies on the conformational changes in the bacterial cell wall biosynthetic enzyme UDP-N-acetylglucosamine enolpyrulvyltransferase (MurA). European Journal of Biochemistry. 253:1998;406-412.
17. Hakenbeck R. Resistance to glycopeptide antibiotics. Ghuysen J-M., Hakenbeck R., Bacterial Cell Wall. 1994;535-543 Elsevier, New York.
18. Ge M., Chen Z., Onishi H. R. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala. Science. 284:1999;507-511.
19. Peisach D., Chipman D. M., VanOphem P. W. D-cycloserine inactivation of D-amino acid aminotransferase leads to a stable noncovalent protein complex with an aromatic cycloserine-PLP derivative. Journal Of The American Chemical Society. 120:1998;2268-2274.
20. Crouvoisier M., Mengin-Lecreulx D., van Heijenoort J. UDP-N-acetylglucosamine transferase from Escherichia coli: overproduction, solubilization, and purification. FEBS Letters. 449:1999;289-292.
21. Eid C. N., Nesler M. J., ZiaEbrahimi M. Synthesis of a radioiodinated park nucleotide analog: A new tool for antibacterial screen development. Journal Of Labelled Compounds & Radiopharmaceuticals. 41:1998;705-716.
22. Bertrand J. A., Auger G., Martin L. Determination of the MurD mechanism through crystallographic analysis of enzyme complexes. Journal Of Molecular Biology. 1999;289 579-590.
23. Miller D. J., Hammond S. M., Anderluzzi D. Aminoalkylphosphinate inhibitors of D-Ala-D-Ala adding enzyme. Journal Of The Chemical Society-Perkin Transactions. 1:1998;131-142.
24. Reddy S. G., Waddell S. T., Kuo D. W. Preperative enzymatic synthesis and characterization of the cytoplasmic intermediates of murein biosynthesis. Journal Of The American Chemical Society. 121:1999;1175-1178.
25. Labischinski H. Consequences of the interaction of β-lactam antibiotics with penicillin binding proteins from sensitive and resistant Staphylococcus aureus strains. Med Microbiol Immunol. 181:1992;241-265.
26. Chambers H. F., Sachdeva M. Binding of β-lactam antibiotics to penicillin-binding proteins in methicillin-resistant Staphylococcus aureus. J Infect Dis. 161:1990;1170-1176.
27. Komatsuzawa H., Choi G. H., Ohta H. Cloning and characterization of a gene, pbpF, encoding a new penicillin-binding protein, PBP2B, in Staphylococcus aureus. Antimicrobial Agents And Chemotherapy. 43:1999;1578-1583.
28. Hartmann B. J., Tomasz A. Low affinity penicillin binding protein associated with β-lactam resistance in Staphylococcus aureus. J Bacteriol. 158:1984;513-516.
29. Beck W. D., Berger-Bächi B., Kayser F. H. Additional DNA in methicillin-resistant Staphylococcus aureus and molecular cloning of mec-spezific DNA. J Bacteriol. 165:1986;373-378.
30. Matthews P. R., Reed K. C., Stewart P. R. The cloning of chromosmal DNA associated with methicillin and other resistance in Staphylococcus aureus. J Gen Microbiol. 133:1987;1919-1929.
31. Ito T., Katayama Y., Hiramatsu K. Cloning and nucleotide sequence determination of the entire mec DNA of pre-methicillin-resistant Staphylococcus aureus N315. Antimicrobial Agents And Chemotherapy. 43:1999;1449-1458.
32. Lu W. P., Sun Y. P., Bauer M. D. Penicillin-binding protein 2a from methicillin-resistant Staphylococcus aureus: Kinetic characterization of its interactions with beta-lactams using electrospray mass spectrometry. Biochemistry. 38:1999;6537-6546.
33. Blais J., Hoang M. K., Chamberland S. F-015 Survey of Clinical Isolates of Methicillin Resistant Staphylococcus aureus (MRSA) for Susceptibility to MC-02, 479/RWJ-54428, a New Cephalosporin. Abstract F-015 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego September 24-27. 1998.
34. Hohl P., Angehrn P., Then R. L. F-024 Ro 63-9141, a Novel Broad-Spectrum Anti-MRSA Pyrrolidinone Cephalosporin. Part II: Activity Against Gram-Positives Including MRSA. Abstract F-024 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego September 24-27. 1998.
35. Ehlert K. Methicillin-resistance in Staphylococcus aureus - Molecular basis, novel targets and antibiotic therapy. Current Pharmaceutical Design. 5:1999;45-55.
36. Berger-Bächi B., Tschierske M. Role of Fem factors in methicillin resistance. Drug Resistance Updates. 1:1998;325-335.
37. de Lencastre H., Tomasz A. Reassessment of the number of auxiliary genes essential for expression of high-leveö methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 38:1994;2590-2598.
38. Vasilieva E., Labischinski H., Berger-Bächi B. Identification and Mapping of New Chromosomal Sites Affecting Response to Beta-lactams in Staphylococcus aureus. Int J Antimicrob Agents. 8:1997;13-21.
39. Komatsuzawa H., Ohta K., Labischinski H. Characterization of fmtA, a Gene That Modulates the Expression of Methicillin Resistance in Staphylococcus aureus. Antimicrobial Agents And Chemotherapy. 1999.
40. Labischinski H., Ehlert K., Berger-Bächi B. The targeting of factors necessary for expression of methicillin resistance in Staphylococci. J Antimicrob Chemother. 41:1998;581-584.
41. Ling B. D., Berger-Bächi B. Increased overall antibiotic susceptibility in Staphylococcus aureus femAB null mutants. Antimicrobial Agents And Chemotherapy. 42:1998;936-938.
42. Labischinski H., Ehlert K., Wieland B. Novel anti-staphylococcal targets and compounds. Exp Opin Invest Drugs. 7:1998;1245-1256.
43. Stranden A. M., Ehlert K., Labischinski H. Cell wall monoglycine cross-bridges and methicillin hypersusceptibility in a femAB null mutant of methicillin-resistant Staphylococcus aureus. Journal Of Bacteriology. 179:1997;9-16.
44. Kopp U., Roos M., Wecke J. Staphylococcal peptidoglycan interpeptide bridge biosynthesis: a novel antistaphylococcal target? Microbial Drug Resistance-Epidemiology and Disease. 2:1996;29-41.
45. Tschierske M., Mori C., Ehlert K. Identification of three additional femAB-like open reading frames in Staphylococcus aureus. FEMS Microbiology Letters. 171:1999;97-102.
46. Sugai M., Fujiwara T., Komatsuzawa H. Identification and molecular characterization of a gene homologous to epr (endopeptidase resistance gene) in Staphylococcus aureus. Gene. 224:1998;67-75.
47. Thumm G., Gotz F. Studies on prolysostaphin processing and characterization of the lysostaphin immunity factor (Lif) of Staphylococcus simulans biovar staphylolyticus. Molecular Microbiology. 23:1997;1251-1265.
48. Tschierske M., Ehlert K., Stranden A. M. Lif, the lysostaphin immunity factor, complements FemB in staphylococcal peptidoglycan interpeptide bridge formation. FEMS Microbiology Letters. 153:1997;261-264.
49. Rohrer, S. Ehlert, K. Tschierske, M. The essential Staphylococcus aureus fmhB gene is involved in the first step of peptidoglycan pentaglycine interpeptide formation. Proc Nat Acad Sci USA 1999 (in press).
50. Alborn W. E., Hoskins J., Ünal S. Cloning and characterization of femA and femB from Staphylococcus epidermidis. Gene. 180:1996;177-178.
51. Vannuffel P., Heusterspreute M., Bouyer M. Molecular characterization of femA from Staphylococcus hominis and Staphylococcus saprophyticus, and femA-based discrimination of staphylococcal species. Research In Microbiology. 150:1999;129-141.
52. TonThat H., Labischinski H., Berger-Bächi B. Anchor structure of staphylococcal surface proteins III. Role of the femA, femB, and femX factors in anchoring surface proteins to the bacterial cell wall. Journal Of Biological Chemistry. 273:1998;29143-29149.
53. Brotz H., Bierbaum G., Leopold K. The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. Antimicrobial Agents And Chemotherapy. 42:1998;154-160.
54. Kimura K., Ikeda Y., Kagami S. Selective inhibition of the bacterial peptidoglycan biosynthesis by the new types of liposidomycins. Journal Of Antibiotics. 51:1998;1099-1104.